Clinical Trial Update: Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating short-term effects of intravitreal aflibercept 2.0 mg as a predictor of long-term outcomes in age-related macular degen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Retina Research Institute, LLC | Conditions: Age Related Macular Degeneration | Phase 4 | Status: UNKNOWN